Nycomed Pharma's Instanyl Sets New Standard In Management Of Breakthrough Cancer Pain, La Maddalena Cancer Center Study

EurekAlert! -- Lisbon, Portugal 11 September, 2009 – New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer. The study concludes that pain relief was significantly greater for Instanyl compared to OTFC at all time points: